Developer docs
API playgroundTry for free, no card

Search company profiles

MolecuLight

Full company profile

uuid00008k9

Namestring
MolecuLight
Legal namestring
MolecuLight Inc.
Websiteurl
moleculight.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescence wound imaging, point-of-care diagnostics, medical imaging devices, bacterial detection systems, wound measurement devices
Industry2 codes
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

MolecuLight generates revenue primarily from the sale of its MolecuLight i:X and DX fluorescence imaging devices, which are FDA Class II cleared, CE marked, and Health Canada approved handheld wound imaging systems. Device sales are made directly in the US and Canada and through authorized distributors globally.

moleculight.com
2Accessories and Consumables
TypeHardware Sales
Description

MolecuLight sells accessories including DarkDrape (for creating clinical darkness), WoundStickers (for wound measurement), and i:X Sterile Surgical Sleeve Convenience Kit (one-time use, disposable items). These consumables generate recurring revenue as procedures are performed.

moleculight.com
3Reimbursement via CPT Codes
TypeSubscription Recurring
Description

The MolecuLight procedure qualifies for reimbursement in the United States through two CPT Category III codes for 'fluorescence imaging for bacterial presence, location, and load'. Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) facility payment is available through APC assignment. This provides a reimbursement pathway supporting healthcare provider adoption.

us.moleculight.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Medical device with pricing provided via quote; no public pricing listed
ModelOtherBilling cadenceOther
Notes

MolecuLight i:X and DX devices are sold through direct sales and authorized distributors. Pricing is not publicly disclosed and is provided upon request/quote. The company offers financing options for customers.

moleculight.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MolecuLight i:X
Description

First FDA-cleared handheld fluorescence imaging device for real-time detection of bacterial burden in wounds at point-of-care

moleculight.com
+1 more record
Core offering1 text field

MolecuLight develops and manufactures FDA-cleared Class II handheld fluorescence imaging devices (MolecuLight i:X and MolecuLight DX) that detect elevated bacterial burden in wounds in real time at the point of care using safe violet excitation light. The flagship MolecuLight DX additionally combines digital wound measurement and thermal imaging in a single device for wound care clinicians, hospitals, and outpatient wound care clinics. The company also sells associated consumable accessories such as DarkDrape, WoundStickers, and sterile surgical sleeves.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 11 values shown
  • 79% greater reduction in wound area by 12 weeks when harmful bacteria detected by MolecuLight are removed
+10 more records
Product overview1 text field

MolecuLight offers a portfolio of point-of-care fluorescence imaging devices for wound care. The core products are the MolecuLight i:X and MolecuLight DX — handheld FDA-cleared Class II medical devices that provide real-time detection of elevated bacterial burden (>104 CFU/g) in wounds through fluorescence imaging, along with digital wound measurement capabilities. The DX model represents the enhanced platform with additional thermal imaging features. The product suite includes accessories such as the i:X Sterile Surgical Sleeve Convenience Kit for use in operating rooms, DarkDrape for creating imaging darkness, and WoundStickers for wound measurement. The company operates under an ISO 13485:2016 Quality Management System and has achieved FDA clearance, CE marking, and Health Canada approval.

Product and service5 records
1MolecuLight DX
CategoryMedical Imaging Device
Description

All-in-one handheld point-of-care wound imaging device that combines fluorescence imaging for real-time detection of elevated bacterial burden (>104 CFU/g) in wounds, digital wound measurement (>95% accuracy), and thermal imaging (±0.5°C accuracy). FDA Class II cleared and the only wound care device also qualified by the FDA as a Medical Device Development Tool (MDDT). For wound care clinicians, hospitals, long-term care facilities, and burn centers.

2MolecuLight i:X
CategoryMedical Imaging Device
Description

Handheld FDA-cleared Class II fluorescence imaging device for point-of-care detection of elevated bacterial burden (>104 CFU/g) in wounds. Allows clinicians to view, digitally record, and measure wounds while detecting bacterial presence through fluorescence using safe violet excitation light, with red fluorescence indicating general bacteria and cyan fluorescence specifically indicating Pseudomonas aeruginosa.

3i:X Sterile Surgical Sleeve Convenience Kit
CategoryDevice Accessory / Consumable
Description

FDA-cleared kit enabling wound care practitioners to safely use the MolecuLight i:X in sterile fields. Includes sterile sleeve, non-sterile adhesive adapter, sterile paper ruler, and instructions for use.

4DarkDrape
CategoryDevice Accessory / Consumable
Description

Wound care accessory that creates the darkness needed to capture MolecuLight fluorescence images when room lights cannot be turned off during wound imaging procedures.

5WoundStickers
CategoryDevice Accessory / Consumable
Description

Disposable stickers placed on either side of wounds for digital wound measurement using the MolecuLight i:X and DX imaging devices.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOthersAnnounced on2026-01-13
Description

University Health Network (UHN), Canada's largest research hospital network, exclusively licensed U.S. Patent No. 10,438,356 to MolecuLight. This patent covers the fluorescence imaging technology used for real-time visualization of bacteria in wounds. MolecuLight founder Dr. Ralph DaCosta is a scientist at Princess Margaret Cancer Centre, part of UHN.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

Net Health integrated MolecuLight's wound imaging devices with its Tissue Analytics platform, enabling improved bacterial detection and data analytics for wound care providers. The integration enhances interoperability with Net Health's WoundExpert and other EHR systems, supporting automated documentation and comprehensive wound assessment.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-09
Description

MolecuLightDX became available on Oracle Healthcare Marketplace, enabling direct connection with Oracle's EHR system. The device integrates bacterial detection, digital wound measurements, and thermal imaging through Oracle's healthcare platform to improve wound care workflows.

Strategic tierSignificantTypeTechnology or IntegrationAnnounced on2023-04-01
Description

MolecuLight Corp. entered into a partnership with Perceptive Solutions to integrate its bacterial imaging technology with the WoundZoom platform, extending the reach of MolecuLight's wound imaging capabilities through Perceptive Solutions' wound measurement technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-01
Description

Premier, Inc. awarded MolecuLight a group purchasing agreement for its i:X and DX point-of-care wound imaging devices in the Skin Integrity category. Premier's alliance includes more than 4,400 U.S. hospitals and 225,000 other healthcare providers who can access special pricing and terms pre-negotiated by Premier. MolecuLight also received Premier's Technology Breakthrough designation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Kent Imaging is a Canadian medical imaging company developing near-infrared fluorescence imaging devices (including SnapshotGLO) for wound and tissue perfusion assessment. It is the most direct competitor to MolecuLight, named as a respondent in MolecuLight's ITC patent infringement complaint.

TypeDirect peer
Description

Spectral AI (formerly SpectralMD) develops DeepView, an AI-driven multispectral imaging system that assesses wound healing potential by analyzing tissue viability. It targets the same wound care clinical market as MolecuLight with a complementary optical imaging approach.

TypeDirect peer
Description

HyperMed Imaging produces hyperspectral imaging devices (HyperView) used to assess tissue oxygenation and perfusion in wounds and burn injuries. It competes with MolecuLight in point-of-care optical wound assessment, particularly in burn and vascular wound applications.

TypeDirect peer
Description

Adiuvo Diagnostics is an India-based developer of fluorescence-based wound imaging technology (subject of MolecuLight's ITC complaint and a contested Indian patent). It is a direct competitor in the multi-spectral fluorescence pathogen detection space.

TypeOthers
Description

Net Health is a wound care EHR and analytics platform (including Tissue Analytics and WoundExpert) that MolecuLight integrates with. It is a channel/integration partner rather than a direct competitor, providing wound care documentation workflows that incorporate MolecuLight's imaging data.

6Perceptive Solutions
TypeOthers
Description

Perceptive Solutions develops the WoundZoom digital wound measurement platform, integrated with MolecuLight's bacterial imaging. It is a complementary technology partner in the wound care documentation ecosystem rather than a direct imaging competitor.

TypeBroad incumbent
Description

Smith+Nephew is a large global medical device company with a substantial Advanced Wound Management portfolio (including PICO, ACTICOAT, and ALLEVYN). As a broad incumbent, it overlaps with MolecuLight in serving wound care clinicians and hospitals, though its focus is on dressings and NPWT rather than point-of-care diagnostic imaging.

TypeBroad incumbent
Description

ConvaTec is a major wound and ostomy care company offering dressings, skin barriers, and related consumables through its Advanced Wound Care franchise. It addresses the same wound care customer base as MolecuLight but focuses on therapeutic products rather than diagnostic imaging devices.

TypeBroad incumbent
Description

Mölnlycke Health Care is a Swedish medical device company specializing in wound care (Mepilex, Mepitel, Avance NPWT) and surgical solutions. It is a broad incumbent in wound care selling to the same hospital and clinician customers as MolecuLight, but without a point-of-care imaging offering.

TypeBroad incumbent
Description

Coloplast is a Danish medical device company with a strong Wound Care business (Biatain, Comfeel) alongside its Ostomy and Continence Care franchises. It serves the same chronic wound patient population and clinician customers as MolecuLight but is focused on therapeutic consumables rather than diagnostic imaging technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MolecuLight

Medical Imaging Devicesmoleculight.com

MolecuLight firmographics

Firmographics
Name
MolecuLight
Legal name
MolecuLight Inc.
Website
https://moleculight.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

MolecuLight industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Fluorescence wound imaging
  • Point-of-care diagnostics
  • Medical imaging devices
  • Bacterial detection systems
  • Wound measurement devices

Where MolecuLight is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

MolecuLight business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales: MolecuLight generates revenue primarily from the sale of its MolecuLight i:X and DX fluorescence imaging devices, which are FDA Class II cleared, CE marked, and Health Canada approved handheld wound imaging systems. Device sales are made directly in the US and Canada and through authorized distributors globally.
  2. Accessories and Consumables: MolecuLight sells accessories including DarkDrape (for creating clinical darkness), WoundStickers (for wound measurement), and i:X Sterile Surgical Sleeve Convenience Kit (one-time use, disposable items). These consumables generate recurring revenue as procedures are performed.
  3. Reimbursement via CPT Codes: The MolecuLight procedure qualifies for reimbursement in the United States through two CPT Category III codes for 'fluorescence imaging for bacterial presence, location, and load'. Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) facility payment is available through APC assignment. This provides a reimbursement pathway supporting healthcare provider adoption.

Pricing tiers

ModelBillingPrice
OtherOtherMedical device with pricing provided via quote; no public pricing listed

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

MolecuLight product offering

Product offering

Core offering

MolecuLight develops and manufactures FDA-cleared Class II handheld fluorescence imaging devices (MolecuLight i:X and MolecuLight DX) that detect elevated bacterial burden in wounds in real time at the point of care using safe violet excitation light. The flagship MolecuLight DX additionally combines digital wound measurement and thermal imaging in a single device for wound care clinicians, hospitals, and outpatient wound care clinics. The company also sells associated consumable accessories such as DarkDrape, WoundStickers, and sterile surgical sleeves.

Product overview

MolecuLight offers a portfolio of point-of-care fluorescence imaging devices for wound care. The core products are the MolecuLight i:X and MolecuLight DX — handheld FDA-cleared Class II medical devices that provide real-time detection of elevated bacterial burden (>104 CFU/g) in wounds through fluorescence imaging, along with digital wound measurement capabilities. The DX model represents the enhanced platform with additional thermal imaging features. The product suite includes accessories such as the i:X Sterile Surgical Sleeve Convenience Kit for use in operating rooms, DarkDrape for creating imaging darkness, and WoundStickers for wound measurement. The company operates under an ISO 13485:2016 Quality Management System and has achieved FDA clearance, CE marking, and Health Canada approval.

Differentiator

Problem solved

Functional benefit

Brands

  • MolecuLight i:X: First FDA-cleared handheld fluorescence imaging device for real-time detection of bacterial burden in wounds at point-of-care
  • MolecuLight DX

Products and services

  • MolecuLight DX All-in-one handheld point-of-care wound imaging device that combines fluorescence imaging for real-time detection of elevated bacterial burden (>104 CFU/g) in wounds, digital wound measurement (>95% accuracy), and thermal imaging (±0.5°C accuracy). FDA Class II cleared and the only wound care device also qualified by the FDA as a Medical Device Development Tool (MDDT). For wound care clinicians, hospitals, long-term care facilities, and burn centers.
  • MolecuLight i:X Handheld FDA-cleared Class II fluorescence imaging device for point-of-care detection of elevated bacterial burden (>104 CFU/g) in wounds. Allows clinicians to view, digitally record, and measure wounds while detecting bacterial presence through fluorescence using safe violet excitation light, with red fluorescence indicating general bacteria and cyan fluorescence specifically indicating Pseudomonas aeruginosa.
  • i:X Sterile Surgical Sleeve Convenience Kit FDA-cleared kit enabling wound care practitioners to safely use the MolecuLight i:X in sterile fields. Includes sterile sleeve, non-sterile adhesive adapter, sterile paper ruler, and instructions for use.
  • DarkDrape Wound care accessory that creates the darkness needed to capture MolecuLight fluorescence images when room lights cannot be turned off during wound imaging procedures.
  • WoundStickers Disposable stickers placed on either side of wounds for digital wound measurement using the MolecuLight i:X and DX imaging devices.

Quantifiable outcome

  • 79% greater reduction in wound area by 12 weeks when harmful bacteria detected by MolecuLight are removed
  • +10 more outcomes

Companies that use MolecuLight

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles3 records

MolecuLight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature6 records

MolecuLight partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and significant.

  • University Health Network (UHN)coreOthers · 13 January 2026University Health Network (UHN), Canada's largest research hospital network, exclusively licensed U.S. Patent No. 10,438,356 to MolecuLight. This patent covers the fluorescence imaging technology used for real-time visualization of bacteria in wounds. MolecuLight founder Dr. Ralph DaCosta is a scientist at Princess Margaret Cancer Centre, part of UHN.
  • Net HealthcoreTechnology or Integration · 16 December 2025Net Health integrated MolecuLight's wound imaging devices with its Tissue Analytics platform, enabling improved bacterial detection and data analytics for wound care providers. The integration enhances interoperability with Net Health's WoundExpert and other EHR systems, supporting automated documentation and comprehensive wound assessment.
  • OraclecoreTechnology or Integration · 9 December 2025MolecuLightDX became available on Oracle Healthcare Marketplace, enabling direct connection with Oracle's EHR system. The device integrates bacterial detection, digital wound measurements, and thermal imaging through Oracle's healthcare platform to improve wound care workflows.
  • Perceptive SolutionssignificantTechnology or Integration · 1 April 2023MolecuLight Corp. entered into a partnership with Perceptive Solutions to integrate its bacterial imaging technology with the WoundZoom platform, extending the reach of MolecuLight's wound imaging capabilities through Perceptive Solutions' wound measurement technology.
  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 June 2022Premier, Inc. awarded MolecuLight a group purchasing agreement for its i:X and DX point-of-care wound imaging devices in the Skin Integrity category. Premier's alliance includes more than 4,400 U.S. hospitals and 225,000 other healthcare providers who can access special pricing and terms pre-negotiated by Premier. MolecuLight also received Premier's Technology Breakthrough designation.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

MolecuLight competitors and assessment

Company assessment

Direct peers

  • Kent Imaging: Kent Imaging is a Canadian medical imaging company developing near-infrared fluorescence imaging devices (including SnapshotGLO) for wound and tissue perfusion assessment. It is the most direct competitor to MolecuLight, named as a respondent in MolecuLight's ITC patent infringement complaint.
  • Spectral AI: Spectral AI (formerly SpectralMD) develops DeepView, an AI-driven multispectral imaging system that assesses wound healing potential by analyzing tissue viability. It targets the same wound care clinical market as MolecuLight with a complementary optical imaging approach.
  • HyperMed Imaging: HyperMed Imaging produces hyperspectral imaging devices (HyperView) used to assess tissue oxygenation and perfusion in wounds and burn injuries. It competes with MolecuLight in point-of-care optical wound assessment, particularly in burn and vascular wound applications.
  • Adiuvo Diagnostics: Adiuvo Diagnostics is an India-based developer of fluorescence-based wound imaging technology (subject of MolecuLight's ITC complaint and a contested Indian patent). It is a direct competitor in the multi-spectral fluorescence pathogen detection space.

Others

  • Net Health: Net Health is a wound care EHR and analytics platform (including Tissue Analytics and WoundExpert) that MolecuLight integrates with. It is a channel/integration partner rather than a direct competitor, providing wound care documentation workflows that incorporate MolecuLight's imaging data.
  • Perceptive Solutions: Perceptive Solutions develops the WoundZoom digital wound measurement platform, integrated with MolecuLight's bacterial imaging. It is a complementary technology partner in the wound care documentation ecosystem rather than a direct imaging competitor.

Broad incumbents

  • Smith+Nephew: Smith+Nephew is a large global medical device company with a substantial Advanced Wound Management portfolio (including PICO, ACTICOAT, and ALLEVYN). As a broad incumbent, it overlaps with MolecuLight in serving wound care clinicians and hospitals, though its focus is on dressings and NPWT rather than point-of-care diagnostic imaging.
  • ConvaTec: ConvaTec is a major wound and ostomy care company offering dressings, skin barriers, and related consumables through its Advanced Wound Care franchise. It addresses the same wound care customer base as MolecuLight but focuses on therapeutic products rather than diagnostic imaging devices.
  • Mölnlycke Health Care: Mölnlycke Health Care is a Swedish medical device company specializing in wound care (Mepilex, Mepitel, Avance NPWT) and surgical solutions. It is a broad incumbent in wound care selling to the same hospital and clinician customers as MolecuLight, but without a point-of-care imaging offering.
  • Coloplast: Coloplast is a Danish medical device company with a strong Wound Care business (Biatain, Comfeel) alongside its Ostomy and Continence Care franchises. It serves the same chronic wound patient population and clinician customers as MolecuLight but is focused on therapeutic consumables rather than diagnostic imaging technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

MolecuLight social profiles

Digital presence

MolecuLight compliance and trust

Trust signal

Compliance6 records

MolecuLight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MolecuLight leadership team

Management profile

Number of profiles

Profiles11 records

MolecuLight subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

MolecuLight funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MolecuLight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MolecuLight

What does MolecuLight do?

MolecuLight develops and manufactures FDA-cleared Class II handheld fluorescence imaging devices (MolecuLight i:X and MolecuLight DX) that detect elevated bacterial burden in wounds in real time at the point of care using safe violet excitation light. The flagship MolecuLight DX additionally combines digital wound measurement and thermal imaging in a single device for wound care clinicians, hospitals, and outpatient wound care clinics. The company also sells associated consumable accessories such as DarkDrape, WoundStickers, and sterile surgical sleeves.

Is MolecuLight a public or private company?

MolecuLight is a private company. It is classified as venture growth investor backed and is currently operating.

When was MolecuLight founded?

MolecuLight was founded in 2012. It employs 51 to 100 people.

Where is MolecuLight based?

MolecuLight is headquartered in Toronto, Canada, in the North America region.

How does MolecuLight make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are accessories and Consumables and reimbursement via CPT Codes.

Who are MolecuLight's main competitors?

Direct peers on record are Kent Imaging, Spectral AI, HyperMed Imaging and Adiuvo Diagnostics. Others are Net Health and Perceptive Solutions. Broad incumbents are Smith+Nephew, ConvaTec, Mölnlycke Health Care and Coloplast.

Does MolecuLight have an API?

No public API is recorded for MolecuLight.

What industry is MolecuLight in?

MolecuLight's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire/C O R R E C T I O N - MolecuLight Corp./MolecuLight announced that its MolecuLightDX+ wound imaging device's encryption module achieved FIPS 140-3 validation, with certificate #5533 issued on September 28, 2026. The validation confirms the module meets U.S. government security standards for protecting sensitive patient information.AktienMolecuLight Named Frost & Sullivan's 2026 Global Company of the Year in Wound ImagingMolecuLight received Frost & Sullivan's 2026 Global Company of the Year Award in wound imaging. The recognition highlights its FDA-cleared handheld devices that combine bacterial fluorescence, digital measurement, and thermal imaging, with clinical evidence supporting improved healing and reduced antibiotic use.AktienMolecuLight wurde von Frost & Sullivan zur 2026 Global Company of the Year im Bereich Wound Imaging ernanntMolecuLight received the Frost & Sullivan 2026 Global Company of the Year award in wound imaging. The award recognizes its FDA-cleared wound imaging systems, clinical evidence of improved healing and reduced antibiotic use, and SOC 2 and FIPS certifications. The company's CEO highlighted the integration of clinical imaging with practical workflows.PR NewswireMolecuLight, nombrada «Empresa global del año 2026» por Frost & Sullivan en imagenología de heridasMolecuLight received Frost & Sullivan's 2026 Global Company of the Year award in wound imaging. The recognition highlights its FDA-approved devices that combine fluorescence-based bacterial detection, digital wound measurement, and thermography, supported by clinical evidence and SOC 2 Type II and FIPS certifications.PR NewswireMolecuLight wurde von Frost & Sullivan zur 2026 Global Company of the Year im Bereich Wound Imaging ernanntMolecuLight received the Frost & Sullivan 2026 Global Company of the Year award in wound imaging. The award recognizes its FDA-cleared wound imaging systems, clinical evidence of improved healing and reduced antibiotic use, and SOC 2 and FIPS certifications. The company's CEO highlighted the integration of clinical imaging with practical workflows.PR NewswireMolecuLight nommée entreprise mondiale de l'année 2026 par Frost & Sullivan dans le domaine de l'imagerie des plaiesMolecuLight was named Frost & Sullivan's 2026 Global Company of the Year in wound imaging. The award recognizes its FDA-approved portable platform combining bacterial fluorescence, wound measurement, and thermal imaging, with clinical evidence of improved healing and reduced antibiotic use.PR NewswireMolecuLight Named Frost & Sullivan's 2026 Global Company of the Year in Wound ImagingMolecuLight received Frost & Sullivan's 2026 Global Company of the Year Award in wound imaging. The recognition highlights its FDA-cleared handheld devices for bacterial fluorescence, digital measurement, and thermal imaging, with clinical evidence supporting improved healing and reduced antibiotic use.PR NewswireMolecuLight Named Frost & Sullivan's 2026 Global Company of the Year in Wound ImagingMolecuLight received Frost & Sullivan's 2026 Global Company of the Year Award in wound imaging. The recognition highlights its FDA-cleared handheld devices for bacterial fluorescence, digital wound measurement, and thermal imaging, with clinical evidence supporting improved healing and reduced antibiotic use.PR NewswireNewly Published Research Highlights MolecuLight's Ability to Predict CAMP Success and Improve Wound Bed ReadinessMolecuLight published two studies showing its fluorescence imaging predicts CAMP success by detecting bacterial burden. In one study, 85.6% of wounds without bacterial fluorescence succeeded versus 14.4% with it; another found over 40% wound area reduction in fluorescence-negative wounds. The findings support using MolecuLight to guide wound bed preparation before CAMP placement.BioSpaceFirst Published Clinical Study Demonstrates Feasibility of Fluorescence Imaging in Orthopaedic SurgeryResearchers at the Royal Orthopaedic Hospital published the first clinical study showing MolecuLight fluorescence imaging can assist in revision knee arthroplasty for periprosthetic joint infection. The 10-patient pilot study found areas of bacterial fluorescence not identified during initial debridement were biopsied and confirmed the same bacterial species. Further larger studies are needed to confirm these findings.